SCHEMBL4898276

SCHEMBL4898276

Cc1cc(C(F)(F)F)c2c(N)c(C(=O)NCCCN(C)c3ccccc3)sc2n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.63
POLB P06746 1/20 0.63
LMNA P02545 2/20 0.56
USP28 Q96RU2 3/20 0.55
USP25 Q9UHP3 1/20 0.55
MAPT P10636 5/20 0.52
USP2 O75604 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
NPC1 O15118 2/20 0.52
ALDH1A1 P00352 2/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
CHRM4 P08173 2/20 0.52
THRB P10828 1/20 0.50
LIMK1 P53667 1/20 0.48
MEN1 O00255 3/20 0.48
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4895200 0.86 USP28 (0.65) KMT2APOLBLMNAUSP28USP25
SCHEMBL4898520 0.84 USP28 (0.72) KMT2APOLBLMNAUSP28USP25
SCHEMBL4896811 0.83 ALDH1A1 (0.61) KMT2APOLBLMNAUSP28USP25
SCHEMBL4896350 0.82 CHRM4 (0.75) KMT2APOLBLMNAUSP28USP25
SCHEMBL4895561 0.82 LMNA (0.61) KMT2APOLBLMNAUSP28USP25
SCHEMBL4898201 0.81 KMT2A (0.59) KMT2APOLBLMNAUSP28USP25
SCHEMBL4893185 0.80 USP28 (0.62) KMT2APOLBLMNAUSP28USP25
SCHEMBL27708047 0.79 USP28 (0.61) KMT2APOLBLMNAUSP28USP25
SCHEMBL4897949 0.79 CHRM4 (0.64) KMT2APOLBLMNAUSP28USP25
SCHEMBL4895299 0.79 USP28 (0.63) KMT2APOLBLMNAUSP28USP25

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US claimed
US-20080306107-A1 Compounds ASTRAZENECA AB (SE) 2008-12-11 US disclosed
EP-1833834-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006068618-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306107-A1 Compounds FURIN, PCSK9, SLC10A1 KMT2A 4760/4885POLB 2561/4885LMNA 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.